# Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

> **NCT06050928** · PHASE1 · COMPLETED · sponsor: **Escient Pharmaceuticals, Inc** · enrollment: 33 (actual)

## Conditions studied

- Chronic Inducible Urticaria

## Interventions

- **DRUG:** Oral EP262

## Key facts

- **NCT ID:** NCT06050928
- **Lead sponsor:** Escient Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-30
- **Primary completion:** 2024-10-22
- **Final completion:** 2024-10-22
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06050928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06050928, "Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06050928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*